Prestige BioPharma Limited (KRX:950210)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,270
0.00 (0.00%)
At close: Jun 5, 2025, 3:30 PM KST
52.53%
Market Cap 159.50B
Revenue (ttm) 8.66B
Net Income (ttm) 21.79B
Shares Out 12.02M
EPS (ttm) 361.82
PE Ratio 36.68
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 85,290
Average Volume 136,850
Open 13,260
Previous Close 13,270
Day's Range 13,060 - 13,290
52-Week Range 8,430 - 20,900
Beta 1.08
RSI 45.44
Earnings Date May 30, 2025

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 54
Stock Exchange Korea Stock Exchange
Ticker Symbol 950210
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.